Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B. Gilbert, Lawrence Corey, Craig A. Magaret et al.|Statistical Communications in Infectious Diseases|2017Cited by 96
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisitionKelly E. Seaton, Georgia D. Tomaras, Yunda Huang et al.|EBioMedicine|2023Cited by 33
Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challengeRena D. Astronomo, M. Juliana McElrath, Maria P. Lemos et al.|Journal of Clinical Investigation|2021Cited by 24
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in AdultsDeborah Theodore, William Smith, Angela R Branche et al.|JAMA Network Open|2023Cited by 23
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Bethany Coomes, Christopher B. Hurt et al.|The Lancet HIV|2024Cited by 12